Conditions: Schizophrenia
Keywords: Schizophrenia Lurasidone Latuda
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 676
Healthy volunteers: no

Brief summary:
Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.

Detailed description:

Arms:
arm 1: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating arm 2: Matching placebo once daily in the evening with a meal or 30 minutes after eating

Interventions: intervention 1: Lurasidone intervention 2: Matching Placebo
Intervention descriptions: intervention 1: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating intervention 2: Matching placebo once daily in the evening with a meal or 30 minutes after eating

Protocol document: